Professor Albert Ong DM MA FRCP
Professor of Renal Medicine
Academic Unit of Nephrology
Department of Infection and Immunity
The University of Sheffield Medical School
Beech Hill Road
Tel: +44 (0)114 271 3402
Fax:: +44 (0)114 271 1711
Secretary: Ms Jean Lazenby
Tel: +44 (0)114 271 2237
Fax: +44 (0)114 271 3892
I am Professor of Renal Medicine and Head of the Academic Unit of Nephrology at the University of Sheffield. After graduating in medicine from the University of Oxford, I underwent postgraduate clinical training in medicine and nephrology at University College London and Oxford. My research career started as a Clinical Lecturer at the Department of Medicine at UCL. I was then awarded a Kidney Research UK Senior Research Fellowship to work under the mentorship of Dr Peter Harris and Sir David Weatherall at the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford.
I received the AEG Raine and CM Lockwood awards from the Renal Association (UK) and a personal Research Leave Fellowship from the Wellcome Trust. I have published over 80 original papers and book chapters in leading journals such as the Lancet, BMJ, PNAS and the EMBO Journal. My research interests are in the impact of the new genetics on kidney disease and in the genetic basis of cystic kidney disease.
I lead the Kidney Genetics Group at the University of Sheffield. Its major research interests are in the molecular genetics, cell biology and pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). In particular, we aim to discover new treatments for ADPKD, to understand better how cysts form and grow in the ADPKD kidney and to improve the clinical management of ADPKD patients.
ADPKD is one of the most common monogenic human diseases known and affects around 1 in 500 people. It is caused by mutations in two genes, PKD1 and PKD2. ADPKD accounts for ~10% of patients with kidney failure in most renal units and affects up to 10 million people worldwide. It is also a major cause of sudden death and disability in younger patients due to intracranial aneurysm rupture.
My educational interests concern the support and development of nephrology in the developing world. I chair the International Committee of the Renal Association and am an Educational Ambassador of the International Society of Nephrology.
- Chair, Renal Association International Committee.
- Chair, UK Kidney Research Consortium (UKKRC) Clinical Study Group on Cystic Kidney Diseases.
- Co-chair, EU PKD Consortium.
- Board member, ERA/EDTA Working Group on Inherited Kidney Diseases (WGIKD)
- Deputy Editor, Nephron Clinical Practice.
- Associate Editor, BMC Nephrology.
- Faculty of 1000 Medicine, Nephrology.
We have taken several experimental approaches to studying ADPKD including:
- Investigating structure-function relationships of the ADPKD proteins, polycystin-1 and polycystin-2.
- The role of post-translational modification in regulating polycystin protein function.
- Using experimental models to understand the natural history of disease and to test novel compounds.
- Pathogenesis of the cardiovascular phenotype in ADPKD.
- Clinical, genetic and epigenetic factors determining renal disease progression in ADPKD patients.
We have a number of active international collaborations. Our work is currently supported by the Wellcome Trust, the Medical Research Council, Research Councils (UK), Kidney Research UK, the Polycystic Kidney disease foundation (USA), the Sheffield Kidney Research Foundation (SKRF), The Sheffield Area Kidney Patients Association (SAKA) and the Polycystic Kidney Disease Charity (UK).
For key publications see below. For a full list of publications click here.
- Ong ACM, Ong ACM, Devuyst O, Devuyst O, Knebelmann B & Walz G (2015) Autosomal dominant polycystic kidney disease: The changing face of clinical management. The Lancet, 385(9981), 1993-2002.
- Simms RJ, Simms RJ, Simms RJ, Travis DL, Durkie M, Wilson G, Dalton A, Ong ACM & Ong ACM (2015) Genetic testing in the assessment of living related kidney donors at risk of autosomal dominant polycystic kidney disease. Transplantation, 99(5), 1023-1029.
- Petzold K, Gansevoort RT, Ong ACM, Devuyst O, Rotar L, Eckardt KU, Köttgen A, Pirson Y, Remuzzi G, Sandford R, Tesar V, Ecder T, Chaveau D, Torra R, Budde K, Le Meur Y, Wüthrich RP & Serra AL (2014) Building a network of ADPKD reference centres across Europe: the EuroCYST initiative.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29 Suppl 4, iv26-iv32.
- Alfieri A, Ong AC, Kammerer RA, Solanky T, Bate S, Tasab M, Brown NJ & Brookes ZL (2014) Angiopoietin-1 regulates microvascular reactivity and protects the microcirculation during acute endothelial dysfunction: role of eNOS and VE-cadherin.. Pharmacol Res, 80, 43-51.
- Chang MY & Ong ACM (2013) New treatments for autosomal dominant polycystic kidney disease. British Journal of Clinical Pharmacology, 76(4), 524-535.
- Ong AC (2013) Primary cilia and renal cysts: does length matter?. Nephrol Dial Transplant, 28(11), 2661-2663.
- Streets AJ, Wessely O, Peters DJ & Ong AC (2013) Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation.. Hum Mol Genet, 22(10), 1924-1939.
- Brookes ZL, Ruff L, Upadhyay VS, Huang L, Prasad S, Solanky T, Nauli SM & Ong AC (2013) Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.. Am J Physiol Heart Circ Physiol, 304(1), H33-H41.
- Chang M-Y & Ong ACM (2012) Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects. NEPHRON CLINICAL PRACTICE, 120(1), C25-C34.
- Giamarchi A, Feng S, Rodat-Despoix L, Xu YX, Bubenshchikova E, Newby LJ, Hao JZ, Gaudioso C, Crest M, Lupas AN, Honore E, Williamson MP, Obara T, Ong ACM & Delmas P (2010) A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J, 29(7), 1176-1191.
- Prasad S, McDaid JP, Tam FW, Haylor JL & Ong AC (2009) Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury.. Am J Pathol, 175(4), 1493-1503. View this article in White Rose Research Online
- Streets AJ, Wagner BE, Harris PC, Ward CJ & Ong AC (2009) Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells.. J Cell Sci, 122(Pt 9), 1410-1417. View this article in White Rose Research Online
- Ong ACM (2009) Screening for intracranial aneurysms in ADPKD. BMJ (Online), 339(7723), 706-707.
- Yu Y, Ulbrich MH, Li MH, Buraei Z, Chen XZ, Ong ACM, Tong L, Isacoff EY, Isacoff EY & Yang J (2009) Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proceedings of the National Academy of Sciences of the United States of America, 106(28), 11558-11563. View this article in White Rose Research Online
- Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O'Hare MJ & Ong AC (2007) Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system.. Kidney Int, 72(2), 157-165.
- Chang MY, Parker E, El Nahas M, Haylor JL & Ong AC (2007) Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.. J Am Soc Nephrol, 18(2), 560-569.
- Streets AJ, Moon DJ, Kane ME, Obara T & Ong AC (2006) Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro.. Hum Mol Genet, 15(9), 1465-1473. View this article in White Rose Research Online
- Ong AC & Harris PC (2005) Molecular pathogenesis of ADPKD: the polycystin complex gets complex.. Kidney Int, 67(4), 1234-1247.
- Ong AC & Wheatley DN (2003) Polycystic kidney disease--the ciliary connection.. Lancet, 361(9359), 774-776.
- Rossetti S, Chauveau D, Kubly V, Slezak JM, Saggar-Malik AK, Pei Y, Ong ACM, Stewart F, Watson ML, Bergstralh EJ, Winearls CG, Torres VE, Harris PC & Harris PC (2003) Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet, 361(9376), 2196-2201.
- Newby LJ, Streets AJ, Zhao Y, Harris PC, Ward CJ & Ong AC (2002) Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex.. J Biol Chem, 277(23), 20763-20773. View this article in White Rose Research Online
- Ong AC, Ward CJ, Butler RJ, Biddolph S, Bowker C, Torra R, Pei Y & Harris PC (1999) Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue.. Am J Pathol, 154(6), 1721-1729.
- Ward CJ, Turley H, Ong AC, Comley M, Biddolph S, Chetty R, Ratcliffe PJ, Gattner K & Harris PC (1996) Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.. Proc Natl Acad Sci U S A, 93(4), 1524-1528.